Dr. Kelly

W. Kevin Kelly, DO

Contact Dr. Kelly

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Multidisciplinary clinical treatment of head and neck cancer
  2. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017
  3. Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer
  4. Naming disease states for clinical utility in prostate cancer: A rose by any other name might not smell as sweet
  5. Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials
  6. PARP Inhibitors in Prostate Cancer
  7. Prevalence and Characteristics of Patients with Suspected Inherited Renal Cell Cancer: Application of the ACMG/NSGC Genetic Referral Guidelines to Patient Cohorts
  8. Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies
  9. Indoleamine 2, 3-dioxygenase (IDO): Biology and target in cancer immunotherapies
  10. A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone for patientswithmetastatic castration-resistant prostate cancer progressing on abiraterone
  11. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report
  12. Pharmacogenetic discovery in CALGB (alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy
  13. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma
  14. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer
  15. Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3
  16. The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3
  17. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer
  18. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)
  19. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer
  20. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy